{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:20:57Z","timestamp":1792092057640,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:10:43Z","timestamp":1757185843000},"page":"62.e1-62.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-888X","authenticated-orcid":false,"given":"Ketty","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath-Reddi","family":"Pingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainjade","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I.","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Laplaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Joel","family":"Decastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.urolonc.2025.08.007_bib0001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.007_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urolonc.2021.09.022","article-title":"Critical shortage in BCG immunotherapy: how did we get here and where will it take us?","volume":"40","author":"Harvey","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.007_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.007_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.007_bib0006","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2024.09.025","article-title":"Navigating the challenges of BCG-unresponsive non-muscle-invasive bladder cancer: insights and future directions","volume":"86","author":"Shariat","year":"2024","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.007_bib0007","first-page":"44","article-title":"FDA approves Pembrolizumab for BCG-unresponsive NMIBC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.007_bib0008","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.eururo.2024.05.027","article-title":"Challenging the paradigm of \"BCG-unresponsive\" bladder cancer: does additional Bacillus Calmette-Guerin have an effect?","volume":"86","author":"Myers","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.007_bib0009","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.007_bib0010","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of Bacillus Calmette-Guerin shortage","volume":"21","author":"Golla","year":"2019","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.007_bib0011","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.007_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive Bladder Cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.007_bib0013","article-title":"Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.007_bib0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.urolonc.2022.09.012","article-title":"Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN updates part III","volume":"41","author":"Reike","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.05.018","article-title":"Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.007_bib0016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical Cabazitaxel, Gemcitabine and Cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Guerin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:59:38Z","timestamp":1765285178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1078143925003138"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}